Anton Rx Report

Mark Cuban can now be called a pharmacy trend setter.  We’ve read about his cost-plus drugs model….. and it seems that Express Scripts (ESI) feels

…………catching up on FDA approvals The FDA has approved a new therapy, Wezlana (ustekinumab-auub) from Amgen, Inc., as a biosimilar to Janssen Biotech’s Stelara. Wezlana is

Here’s an interesting new twist on hospitals and health systems opening their own specialty pharmacies….. PA-based Geisinger Clinic and NY-based Bassett Healthcare are getting hitched to

There was a big development for DMA patients last June with the FDA approval of Elevidys (delandistrogene moxeparvovec-rokl) from Sarepta Therapeutics. Elevidys was the first and

I always enjoy news about innovative developments in pharmacy.  The article below tickled our interest. The article details how Texas A&M has successfully developed a

When a Fortune 100 company breaks the mold on anything it is news. Recently, Tyson Foods made a mold-breaking move and showed it was not averse

There has been scant news over the past year about big moves involving sales and strategic acquisitions in the specialty pharmacy space.  Today my internet

Earlier this week we sent a Report outlining why the term ‘BioBETTER’ should be added to your pharma vocabulary. Today we introduce a new biosimilar that

What is a Biobetter? An article published by the Center for Biosimilars used a new word to the specialty pharmacy lexicon…… BioBetter….. prompting us to

Announcements for newly approved specialty drugs often state that the product will be available through specialty pharmacy in limited distribution. However, the press releases rarely